Overview of neurofilament light chain in mental disorders

Neurofilament light chain (NfL), released following neuroaxonal damage, serves as a biomarker in neurological diseases and shows potential in mental disorders. This narrative review aims to clarify the current research status of NfL in five mental disorders, namely depression, bipolar disorder, schizophrenia, substance use disorder, and anxiety, as well as in electroconvulsive therapy. We conducted a literature review using articles from PubMed, EMBASE, Google Scholar, and Web of Science databases. In depression, most population-based studies supported positive associations between NfL and depressive symptoms, whereas clinical findings were mixed. For bipolar disorder, most studies reported elevated NfL levels compared to healthy controls. In schizophrenia, however, more studies found no significant elevation compared with healthy controls. For substance use disorder, studies reported dynamic changes in NfL across withdrawal stages, with most evidence derived from alcohol dependence. The only study on anxiety disorder lacked patient-control comparisons. Studies on electroconvulsive therapy consistently reported no significant changes in NfL after treatment. Overall, research on NfL in mental disorders remains at a preliminary stage and requires further validation, as well as mechanistic and longitudinal studies.

Authors

Publication Details

Journal
World Journal of Psychiatry
Published
2026-11-19
DOI
https://doi.org/10.5498/wjp.125017
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Overview of neurofilament light chain in mental disorders

Bin Li, Rui-Hua Li, Jia-Meng Li
3 links
World Journal of Psychiatry
Treatment of Major Depression
article

Overview of neurofilament light chain in mental disorders

Bin Li, Rui-Hua Li, Jia-Meng Li
article en

Abstract

Neurofilament light chain (NfL), released following neuroaxonal damage, serves as a biomarker in neurological diseases and shows potential in mental disorders. This narrative review aims to clarify the current research status of NfL in five mental disorders, namely depression, bipolar disorder, schizophrenia, substance use disorder, and anxiety, as well as in electroconvulsive therapy. We conducted a literature review using articles from PubMed, EMBASE, Google Scholar, and Web of Science databases. In depression, most population-based studies supported positive associations between NfL and depressive symptoms, whereas clinical findings were mixed. For bipolar disorder, most studies reported elevated NfL levels compared to healthy controls. In schizophrenia, however, more studies found no significant elevation compared with healthy controls. For substance use disorder, studies reported dynamic changes in NfL across withdrawal stages, with most evidence derived from alcohol dependence. The only study on anxiety disorder lacked patient-control comparisons. Studies on electroconvulsive therapy consistently reported no significant changes in NfL after treatment. Overall, research on NfL in mental disorders remains at a preliminary stage and requires further validation, as well as mechanistic and longitudinal studies.

World Journal of PsychiatryVol. 16(11)
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon